Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00938223 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
A Phase 2 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00938223 is a Phase 2 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 51 participants.
The verdict
NCT00938223, a Phase 2 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is an open-label, phase II study of a vaccine comprising melanoma peptides and a tetanus helper peptide, administered in GM-CSF-in-adjuvant. Patients will be randomized to receive one of two different vaccine regimens. Patients will be stratified by stage of disease (IIB versus III versus IV).
Interventions
- BIOLOGICAL 4-peptide and 12-peptide melanoma vaccines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2000-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00938223
The ClinicalTrials.gov registry entry for NCT00938223 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 4-peptide and 12-peptide melanoma vaccines is the first listed.
NCT00938223 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00938223 about?
NCT00938223 is a clinical study titled "Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma". This is an open-label, phase II study of a vaccine comprising melanoma peptides and a tetanus helper peptide, administered in GM-CSF-in-adjuvant. Patients will be randomized to receive one of two different vaccine regimens. Patients will be stratified by stage of disease (IIB versus III versus IV).
What is the current status of trial NCT00938223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2000-08.
What interventions are being tested in trial NCT00938223?
The interventions under investigation include: 4-peptide and 12-peptide melanoma vaccines (BIOLOGICAL).
Who is sponsoring clinical trial NCT00938223?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.